Subscribe
shutterstock_334985060_lifetimestock
LifetimeStock / Shutterstock.com
13 January 2022Big PharmaAlex Baldwin

PeriRx’s breach of licensing contract suit can’t prevail

Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Bayer and ERS enter CRISPR patent licensing agreement
19 May 2016   Bayer and ERS Genomics have signed a patent licensing agreement which gives Bayer access to ERS’s CRISPR/Cas9 genome-editing patents.
Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Big Pharma
PeriRx sanctioned over false negotiation claims in patent suit
24 January 2022   PeriRx has been hit with sanctions over its conduct after its breach of licensing suit failed in a patent licensing dispute against the University of California.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Europe
Bayer and ERS enter CRISPR patent licensing agreement
19 May 2016   Bayer and ERS Genomics have signed a patent licensing agreement which gives Bayer access to ERS’s CRISPR/Cas9 genome-editing patents.
Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Big Pharma
PeriRx sanctioned over false negotiation claims in patent suit
24 January 2022   PeriRx has been hit with sanctions over its conduct after its breach of licensing suit failed in a patent licensing dispute against the University of California.

More on this story

Europe
Bayer and ERS enter CRISPR patent licensing agreement
19 May 2016   Bayer and ERS Genomics have signed a patent licensing agreement which gives Bayer access to ERS’s CRISPR/Cas9 genome-editing patents.
Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Big Pharma
PeriRx sanctioned over false negotiation claims in patent suit
24 January 2022   PeriRx has been hit with sanctions over its conduct after its breach of licensing suit failed in a patent licensing dispute against the University of California.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?